COMPOSITIONS AND METHODS OF USE FOR SOLUBLE THROMBOMODULIN VARIANTS
    7.
    发明申请
    COMPOSITIONS AND METHODS OF USE FOR SOLUBLE THROMBOMODULIN VARIANTS 审中-公开
    用于可溶性血小板红素变体的组合物和方法

    公开(公告)号:US20110207670A1

    公开(公告)日:2011-08-25

    申请号:US13126474

    申请日:2009-10-21

    CPC分类号: A61K38/366 C07K14/7455

    摘要: The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind thrombin will prevent or reduce acute kidney injury and subsequent morbidity and mortality.

    摘要翻译: 本发明提供一种预防和/或治疗由各种病症引起的急性肾损伤患者的方法。 该方法包括向患者施用不结合凝血酶的可溶性血栓调节蛋白变体。 结合护理标准,不结合凝血酶的可溶性血栓调节蛋白变体将预防或减少急性肾损伤及随后的发病率和死亡率。

    Protein C derivatives
    8.
    发明授权
    Protein C derivatives 失效
    蛋白C衍生物

    公开(公告)号:US06998122B1

    公开(公告)日:2006-02-14

    申请号:US09719911

    申请日:2000-04-13

    摘要: Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially longer half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.

    摘要翻译: 描述了新的蛋白C衍生物。 这些多肽保留野生型人蛋白C的生物学活性,而人血液中的半衰期要长得多。 这些多肽在治疗血管闭塞性障碍,高凝状态,血栓形成障碍以及容易发生血栓形成的疾病状态下,需要比野生型人蛋白C更少频繁的施用和/或更小的剂量。